NASDAQ:MGLN

Magellan Health Competitors

$94.55
-0.06 (-0.06 %)
(As of 07/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$94.53
$94.68
50-Day Range
$94.10
$94.65
52-Week Range
$69.35
$95.43
Volume109,362 shs
Average Volume283,151 shs
Market Capitalization$2.47 billion
P/E Ratio6.21
Dividend YieldN/A
Beta1.22

Magellan Health (NASDAQ:MGLN) Vs. JAZZ, TEVA, NTRA, PEN, NTLA, and SYNH

Should you be buying MGLN stock or one of its competitors? Companies in the sector of "medical" are considered alternatives and competitors to Magellan Health, including Jazz Pharmaceuticals (JAZZ), Teva Pharmaceutical Industries (TEVA), Natera (NTRA), Penumbra (PEN), Intellia Therapeutics (NTLA), and Syneos Health (SYNH).

Magellan Health (NASDAQ:MGLN) and Jazz Pharmaceuticals (NASDAQ:JAZZ) are both mid-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Magellan Health and Jazz Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Magellan Health02102.33
Jazz Pharmaceuticals111402.81

Magellan Health currently has a consensus target price of $93.3333, suggesting a potential downside of 1.29%. Jazz Pharmaceuticals has a consensus target price of $201.0667, suggesting a potential upside of 16.05%. Given Jazz Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Jazz Pharmaceuticals is more favorable than Magellan Health.

Institutional and Insider Ownership

96.5% of Magellan Health shares are owned by institutional investors. Comparatively, 92.0% of Jazz Pharmaceuticals shares are owned by institutional investors. 14.1% of Magellan Health shares are owned by insiders. Comparatively, 4.8% of Jazz Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Magellan Health and Jazz Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Magellan Health$4.58 billion0.54$382.33 million$0.77122.79
Jazz Pharmaceuticals$2.36 billion4.17$238.62 million$10.7716.09

Magellan Health has higher revenue and earnings than Jazz Pharmaceuticals. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than Magellan Health, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Magellan Health has a beta of 1.22, suggesting that its share price is 22% more volatile than the S&P 500. Comparatively, Jazz Pharmaceuticals has a beta of 1.04, suggesting that its share price is 4% more volatile than the S&P 500.

Profitability

This table compares Magellan Health and Jazz Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Magellan Health8.49%2.84%1.47%
Jazz Pharmaceuticals21.27%22.95%12.51%

Summary

Jazz Pharmaceuticals beats Magellan Health on 9 of the 14 factors compared between the two stocks.

Teva Pharmaceutical Industries (NYSE:TEVA) and Magellan Health (NASDAQ:MGLN) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, valuation, earnings, analyst recommendations and profitability.

Insider & Institutional Ownership

52.2% of Teva Pharmaceutical Industries shares are owned by institutional investors. Comparatively, 96.5% of Magellan Health shares are owned by institutional investors. 0.7% of Teva Pharmaceutical Industries shares are owned by insiders. Comparatively, 14.1% of Magellan Health shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Teva Pharmaceutical Industries and Magellan Health's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Teva Pharmaceutical Industries$16.66 billion0.59$-3,990,000,000.00$2.453.65
Magellan Health$4.58 billion0.54$382.33 million$0.77122.79

Magellan Health has lower revenue, but higher earnings than Teva Pharmaceutical Industries. Teva Pharmaceutical Industries is trading at a lower price-to-earnings ratio than Magellan Health, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations for Teva Pharmaceutical Industries and Magellan Health, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Teva Pharmaceutical Industries17202.10
Magellan Health02102.33

Teva Pharmaceutical Industries presently has a consensus target price of $11.25, suggesting a potential upside of 25.84%. Magellan Health has a consensus target price of $93.3333, suggesting a potential downside of 1.29%. Given Teva Pharmaceutical Industries' higher probable upside, equities analysts clearly believe Teva Pharmaceutical Industries is more favorable than Magellan Health.

Profitability

This table compares Teva Pharmaceutical Industries and Magellan Health's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Teva Pharmaceutical Industries-24.45%21.65%5.03%
Magellan Health8.49%2.84%1.47%

Volatility & Risk

Teva Pharmaceutical Industries has a beta of 1.46, suggesting that its stock price is 46% more volatile than the S&P 500. Comparatively, Magellan Health has a beta of 1.22, suggesting that its stock price is 22% more volatile than the S&P 500.

Summary

Teva Pharmaceutical Industries beats Magellan Health on 8 of the 14 factors compared between the two stocks.

Magellan Health (NASDAQ:MGLN) and Natera (NASDAQ:NTRA) are both mid-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, analyst recommendations and institutional ownership.

Profitability

This table compares Magellan Health and Natera's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Magellan Health8.49%2.84%1.47%
Natera-57.47%-59.71%-28.77%

Risk & Volatility

Magellan Health has a beta of 1.22, meaning that its share price is 22% more volatile than the S&P 500. Comparatively, Natera has a beta of 1.31, meaning that its share price is 31% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Magellan Health and Natera, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Magellan Health02102.33
Natera011102.92

Magellan Health currently has a consensus price target of $93.3333, suggesting a potential downside of 1.29%. Natera has a consensus price target of $128.7273, suggesting a potential upside of 16.45%. Given Natera's stronger consensus rating and higher probable upside, analysts plainly believe Natera is more favorable than Magellan Health.

Institutional and Insider Ownership

96.5% of Magellan Health shares are held by institutional investors. Comparatively, 96.0% of Natera shares are held by institutional investors. 14.1% of Magellan Health shares are held by company insiders. Comparatively, 10.9% of Natera shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Magellan Health and Natera's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Magellan Health$4.58 billion0.54$382.33 million$0.77122.79
Natera$391.01 million24.86$-229,740,000.00($2.84)-38.92

Magellan Health has higher revenue and earnings than Natera. Natera is trading at a lower price-to-earnings ratio than Magellan Health, indicating that it is currently the more affordable of the two stocks.

Summary

Magellan Health beats Natera on 9 of the 14 factors compared between the two stocks.

Penumbra (NYSE:PEN) and Magellan Health (NASDAQ:MGLN) are both mid-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, profitability, earnings, risk, institutional ownership and valuation.

Risk & Volatility

Penumbra has a beta of 0.31, suggesting that its stock price is 69% less volatile than the S&P 500. Comparatively, Magellan Health has a beta of 1.22, suggesting that its stock price is 22% more volatile than the S&P 500.

Profitability

This table compares Penumbra and Magellan Health's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Penumbra-0.89%2.69%2.09%
Magellan Health8.49%2.84%1.47%

Analyst Ratings

This is a summary of recent ratings and target prices for Penumbra and Magellan Health, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Penumbra01402.80
Magellan Health02102.33

Penumbra currently has a consensus price target of $310.40, suggesting a potential upside of 18.43%. Magellan Health has a consensus price target of $93.3333, suggesting a potential downside of 1.29%. Given Penumbra's stronger consensus rating and higher possible upside, equities research analysts clearly believe Penumbra is more favorable than Magellan Health.

Institutional & Insider Ownership

84.0% of Penumbra shares are owned by institutional investors. Comparatively, 96.5% of Magellan Health shares are owned by institutional investors. 7.5% of Penumbra shares are owned by insiders. Comparatively, 14.1% of Magellan Health shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Penumbra and Magellan Health's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Penumbra$560.41 million17.06$-15,700,000.00$0.112,382.64
Magellan Health$4.58 billion0.54$382.33 million$0.77122.79

Magellan Health has higher revenue and earnings than Penumbra. Magellan Health is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks.

Summary

Magellan Health beats Penumbra on 9 of the 14 factors compared between the two stocks.

Magellan Health (NASDAQ:MGLN) and Intellia Therapeutics (NASDAQ:NTLA) are both mid-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, analyst recommendations, valuation, institutional ownership, profitability and earnings.

Risk & Volatility

Magellan Health has a beta of 1.22, meaning that its stock price is 22% more volatile than the S&P 500. Comparatively, Intellia Therapeutics has a beta of 2.11, meaning that its stock price is 111% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings for Magellan Health and Intellia Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Magellan Health02102.33
Intellia Therapeutics031402.82

Magellan Health presently has a consensus price target of $93.3333, suggesting a potential downside of 1.29%. Intellia Therapeutics has a consensus price target of $122.0625, suggesting a potential downside of 8.91%. Given Magellan Health's higher probable upside, research analysts clearly believe Magellan Health is more favorable than Intellia Therapeutics.

Profitability

This table compares Magellan Health and Intellia Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Magellan Health8.49%2.84%1.47%
Intellia Therapeutics-288.47%-33.89%-25.38%

Valuation & Earnings

This table compares Magellan Health and Intellia Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Magellan Health$4.58 billion0.54$382.33 million$0.77122.79
Intellia Therapeutics$57.99 million157.49$-134,230,000.00($2.40)-55.83

Magellan Health has higher revenue and earnings than Intellia Therapeutics. Intellia Therapeutics is trading at a lower price-to-earnings ratio than Magellan Health, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

96.5% of Magellan Health shares are held by institutional investors. Comparatively, 91.9% of Intellia Therapeutics shares are held by institutional investors. 14.1% of Magellan Health shares are held by company insiders. Comparatively, 4.1% of Intellia Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Magellan Health beats Intellia Therapeutics on 10 of the 14 factors compared between the two stocks.

Magellan Health (NASDAQ:MGLN) and Syneos Health (NASDAQ:SYNH) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, analyst recommendations, institutional ownership, earnings, risk and profitability.

Institutional & Insider Ownership

96.5% of Magellan Health shares are owned by institutional investors. Comparatively, 91.4% of Syneos Health shares are owned by institutional investors. 14.1% of Magellan Health shares are owned by company insiders. Comparatively, 0.3% of Syneos Health shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Risk & Volatility

Magellan Health has a beta of 1.22, indicating that its stock price is 22% more volatile than the S&P 500. Comparatively, Syneos Health has a beta of 1.83, indicating that its stock price is 83% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Magellan Health and Syneos Health, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Magellan Health02102.33
Syneos Health01802.89

Magellan Health currently has a consensus target price of $93.3333, indicating a potential downside of 1.29%. Syneos Health has a consensus target price of $86.60, indicating a potential downside of 0.74%. Given Syneos Health's stronger consensus rating and higher probable upside, analysts clearly believe Syneos Health is more favorable than Magellan Health.

Profitability

This table compares Magellan Health and Syneos Health's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Magellan Health8.49%2.84%1.47%
Syneos Health4.44%10.23%4.18%

Valuation and Earnings

This table compares Magellan Health and Syneos Health's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Magellan Health$4.58 billion0.54$382.33 million$0.77122.79
Syneos Health$4.42 billion2.06$192.79 million$2.8530.61

Magellan Health has higher revenue and earnings than Syneos Health. Syneos Health is trading at a lower price-to-earnings ratio than Magellan Health, indicating that it is currently the more affordable of the two stocks.

Summary

Syneos Health beats Magellan Health on 9 of the 14 factors compared between the two stocks.


Magellan Health Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Jazz Pharmaceuticals logo
JAZZ
Jazz Pharmaceuticals
2.6$173.26-0.4%$9.86 billion$2.36 billion19.00Upcoming Earnings
Analyst Upgrade
Teva Pharmaceutical Industries logo
TEVA
Teva Pharmaceutical Industries
1.9$8.94-1.5%$9.76 billion$16.66 billion-2.46Upcoming Earnings
Natera logo
NTRA
Natera
1.7$110.54-3.1%$9.72 billion$391.01 million-35.66Insider Buying
Penumbra logo
PEN
Penumbra
1.9$262.09-1.6%$9.56 billion$560.41 million-1,637.96
Intellia Therapeutics logo
NTLA
Intellia Therapeutics
1.4$134.00-2.8%$9.13 billion$57.99 million-54.47
Syneos Health logo
SYNH
Syneos Health
1.6$87.25-1.7%$9.10 billion$4.42 billion46.41
Neurocrine Biosciences logo
NBIX
Neurocrine Biosciences
2.4$95.77-2.9%$9.05 billion$1.05 billion23.36Upcoming Earnings
Analyst Upgrade
CRISPR Therapeutics logo
CRSP
CRISPR Therapeutics
1.4$119.22-2.6%$9.03 billion$720,000.00-21.18
BridgeBio Pharma logo
BBIO
BridgeBio Pharma
1.5$56.31-7.6%$8.41 billion$8.25 million-13.41
Globus Medical logo
GMED
Globus Medical
1.6$82.91-0.2%$8.32 billion$789.04 million69.67News Coverage
Amedisys logo
AMED
Amedisys
1.4$255.17-3.5%$8.31 billion$2.07 billion42.11
United Therapeutics logo
UTHR
United Therapeutics
1.9$183.27-0.7%$8.21 billion$1.48 billion20.25Positive News
Hill-Rom logo
HRC
Hill-Rom
1.7$121.66-0.4%$8.09 billion$2.88 billion28.90Upcoming Earnings
LFST
LifeStance Health Group
1.8$21.48-4.6%$8.03 billion$265.56 million0.00
Encompass Health logo
EHC
Encompass Health
2.0$80.40-1.0%$8.00 billion$4.64 billion26.36Dividend Announcement
News Coverage
Encompass Health logo
EHC
Encompass Health
2.0$80.40-1.0%$8.00 billion$4.64 billion26.36Dividend Announcement
News Coverage
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
1.4$122.34-3.4%$7.96 billion$63.63 million-8.63
Mirati Therapeutics logo
MRTX
Mirati Therapeutics
1.2$152.17-3.3%$7.83 billion$13.40 million-17.69
Fate Therapeutics logo
FATE
Fate Therapeutics
1.6$83.01-3.8%$7.81 billion$31.43 million-39.16Insider Selling
Canopy Growth logo
CGC
Canopy Growth
1.2$19.71-0.5%$7.75 billion$414.03 million-5.46
Tenet Healthcare logo
THC
Tenet Healthcare
1.5$71.67-0.1%$7.65 billion$17.64 billion17.92Earnings Announcement
Analyst Revision
BHG
Bright Health Group
1.8$12.40-1.2%$7.63 billionN/A0.00Upcoming Earnings
Chemed logo
CHE
Chemed
2.3$477.92-0.4%$7.62 billion$2.08 billion23.75
OGN
Organon & Co.
1.1$29.66-0.5%$7.52 billionN/A0.00
Acceleron Pharma logo
XLRN
Acceleron Pharma
1.8$120.19-2.2%$7.30 billion$92.52 million-40.06
Arrowhead Pharmaceuticals logo
ARWR
Arrowhead Pharmaceuticals
1.6$66.73-2.5%$6.95 billion$87.99 million-62.36
Change Healthcare logo
CHNG
Change Healthcare
1.2$22.00-0.9%$6.82 billion$3.09 billion-64.70
Envista logo
NVST
Envista
1.2$41.77-0.6%$6.72 billion$2.28 billion61.43Upcoming Earnings
HUTCHMED logo
HCM
HUTCHMED
1.0$39.28-2.8%$6.67 billion$227.98 million-43.64Gap Down
Denali Therapeutics logo
DNLI
Denali Therapeutics
1.5$54.14-18.0%$6.56 billion$335.66 million235.40Analyst Report
News Coverage
Gap Down
High Trading Volume
High Trading Volume
LHC Group logo
LHCG
LHC Group
1.6$206.95-3.4%$6.55 billion$2.06 billion52.26
Omnicell logo
OMCL
Omnicell
0.8$151.68-0.2%$6.55 billion$892.21 million196.99Upcoming Earnings
Medpace logo
MEDP
Medpace
1.5$181.43-0.4%$6.53 billion$925.92 million42.99Earnings Announcement
Insider Selling
News Coverage
Tandem Diabetes Care logo
TNDM
Tandem Diabetes Care
1.7$102.35-1.6%$6.41 billion$498.83 million-222.50Positive News
Sotera Health logo
SHC
Sotera Health
2.4$22.59-0.9%$6.39 billion$818.16 million59.45
HealthEquity logo
HQY
HealthEquity
1.8$74.62-0.3%$6.22 billion$733.57 million1,243.87
Perrigo logo
PRGO
Perrigo
2.0$46.23-0.2%$6.17 billion$5.06 billion-27.19
Tilray logo
TLRY
Tilray
1.4$13.70-0.8%$6.13 billion$210.48 million-5.07Upcoming Earnings
Apollo Medical logo
AMEH
Apollo Medical
1.3$110.87-1.8%$6.10 billion$687.18 million91.63
Ascendis Pharma A/S logo
ASND
Ascendis Pharma A/S
2.0$112.67-2.7%$6.06 billion$7.94 million-11.95
Pacific Biosciences of California logo
PACB
Pacific Biosciences of California
1.6$30.37-0.1%$6.02 billion$78.89 million-82.08Upcoming Earnings
Halozyme Therapeutics logo
HALO
Halozyme Therapeutics
2.1$42.17-1.7%$6.00 billion$267.59 million37.32Positive News
Quidel logo
QDEL
Quidel
1.6$139.73-7.5%$5.95 billion$1.66 billion6.42
ShockWave Medical logo
SWAV
ShockWave Medical
1.6$169.54-3.0%$5.93 billion$67.79 million-81.51
STAAR Surgical logo
STAA
STAAR Surgical
1.3$126.18-4.5%$5.92 billion$163.46 million573.57
Integra LifeSciences logo
IART
Integra LifeSciences
1.4$69.47-1.4%$5.87 billion$1.37 billion34.74Upcoming Earnings
Positive News
Legend Biotech logo
LEGN
Legend Biotech
1.2$43.93-8.8%$5.84 billion$75.68 million-31.38Gap Down
Twist Bioscience logo
TWST
Twist Bioscience
1.4$115.00-2.0%$5.62 billion$90.10 million-42.44
Beam Therapeutics logo
BEAM
Beam Therapeutics
1.3$89.46-3.2%$5.60 billion$20,000.00-13.93
RXRX
Recursion Pharmaceuticals
1.1$33.21-5.6%$5.59 billion$3.96 million0.00
This page was last updated on 7/27/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.